BlackRock
MRKR icon

BlackRock’s Marker Therapeutics MRKR Stock Holding History

BlackRock’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-992
Closed -$1.48K – 5758
2025
Q4 		$1.48K Hold
992
– – ﹤0.01% 5408
2025
Q3 		$885 Hold
992
– – ﹤0.01% 5355
2025
Q2 		$1.52K Sell
992
-15,276
-94% -$19.6K ﹤0.01% 5335
2025
Q1 		$20K Sell
16,268
-291
-2% -$533 ﹤0.01% 5092
2024
Q4 		$51.5K Sell
16,559
-2,447
-13% -$8.66K ﹤0.01% 4942
2024
Q3 		$53.6K Buy
19,006
+7,980
+72% +$31.6K ﹤0.01% 4799
2024
Q2 		$59.9K Buy
11,026
+10,034
+1,011% +$42.6K ﹤0.01% 4824
2024
Q1 		$4.27K Sell
992
-372
-27% -$1.63K ﹤0.01% 5147
2023
Q4 		$7.5K Hold
1,364
– – ﹤0.01% 5168
2023
Q3 		$6.19K Sell
1,364
-544
-29% -$3.04K ﹤0.01% 5229
2023
Q2 		$5.92K Hold
1,908
– – ﹤0.01% 5294
2023
Q1 		$1.35K Sell
1,908
-10,847
-85% -$25.8K ﹤0.01% 5458
2022
Q4 		$33.9K Buy
12,755
+1,003
+9% +$3.46K ﹤0.01% 5306
2022
Q3 		$43K Sell
11,752
-344
-3% -$1.26K ﹤0.01% 5391
2022
Q2 		$40K Sell
12,096
-14,141
-54% -$47K ﹤0.01% 5461
2022
Q1 		$115K Sell
26,237
-587
-2% -$3.35K ﹤0.01% 5255
2021
Q4 		$255K Buy
26,824
+919
+4% +$12.2K ﹤0.01% 5051
2021
Q3 		$438K Buy
25,905
+50
+0.2% +$1.02K ﹤0.01% 4793
2021
Q2 		$722K Sell
25,855
-181,749
-88% -$4.79M ﹤0.01% 4606
2021
Q1 		$4.65M Buy
207,604
+962
+0.5% +$22K ﹤0.01% 3972
2020
Q4 		$3M Buy
206,642
+10,320
+5% +$160K ﹤0.01% 3899
2020
Q3 		$2.94M Sell
196,322
-709
-0.4% -$12.9K ﹤0.01% 3783
2020
Q2 		$4.08M Buy
197,031
+6,267
+3% +$137K ﹤0.01% 3602
2020
Q1 		$3.62M Sell
190,764
-1,981
-1% -$50.5K ﹤0.01% 3470
2019
Q4 		$5.55M Buy
192,745
+9,210
+5% +$335K ﹤0.01% 3472
2019
Q3 		$9.38M Buy
183,535
+5,460
+3% +$323K ﹤0.01% 3240
2019
Q2 		$14.1M Buy
178,075
+163,023
+1,083% +$9.68M ﹤0.01% 3044
2019
Q1 		$994K Buy
15,052
+13,145
+689% +$767K ﹤0.01% 3916
2018
Q4 		$106K Sell
1,907
-192
-9% -$14K ﹤0.01% 4347
2018
Q3 		$190K Buy
2,099
+85
+4% +$7.3K ﹤0.01% 4325
2018
Q2 		$189K Buy
2,014
+609
+43% +$31.1K ﹤0.01% 4314
2018
Q1 		$47K Sell
1,405
-36
-2% -$1.27K ﹤0.01% 4443
2017
Q4 		$57K Buy
1,441
+58
+4% +$1.78K ﹤0.01% 4416
2017
Q3 		$42K Sell
1,383
-80
-5% -$2.52K ﹤0.01% 4505
2017
Q2 		$57K Buy
+1,463
New +$57.6K ﹤0.01% 4506

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BlackRock's MRKR Position: Q1 2026 in Review

BlackRock sold out of Marker Therapeutics (MRKR) in Q1 2026, closing a stake of 992 shares — an estimated $1.48K sold.

BlackRock first reported a position in MRKR in Q2 2017 and held it in 35 quarters. The position peaked at $14.1M in Q2 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • BlackRock reported no remaining Marker Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BlackRock sold 992 Marker Therapeutics shares in Q1 2026, an estimated $1.48K.
  • BlackRock first reported a position in Marker Therapeutics in Q2 2017 and held it in 35 quarters.
  • BlackRock's Marker Therapeutics position peaked at $14.1M in Q2 2019.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.